Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
32 authors.
Anagh A Sahasrabuddhe *Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-3040-0019
Kaiyu Ma *Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0009-0002-7515-7857
Rui WuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-4956-470X
Huan-Chang LiangDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2612-3714
Richa KapoorDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0002-4183-1332
Rishi R ChhipaDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0009-0003-9858-6651
Ozlem OnderDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0003-0850-1216
Courtney McFetridgeDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0009-0002-6842-8057
John S Van ArnamDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0009-0001-9723-5003
Xiao ZhangDivision of Bone and Mineral Diseases, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0003-2427-0147
Jennifer J D MorrissetteDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0001-9460-7177
Vinodh PillaiDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0001-7126-6226
Marilyn M LiDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0002-4253-2369
Venkatesha BasrurDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.ORCID 0000-0002-0853-9655
Kevin P ConlonDepartment of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.ORCID 0009-0003-8008-1145
Tobias D RaabeDivision of Translational Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-8944-3278
Nathanael G BaileyDepartment of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-6747-680X
Cory M HogaboamDepartment of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, California.ORCID 0000-0003-3366-4850
Robert RottapelPrincess Margaret Cancer Centre, Toronto Medical Discovery Tower, Toronto, Canada.ORCID 0000-0002-6024-5558
Junhyong KimDepartment of Biology, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0002-7726-8246
Cristina LópezInstitute of Human Genetics, Ulm University and Ulm Medical Center, Ulm, Germany.ORCID 0000-0001-6644-1659
Matthias SchlesnerBiomedical Informatics, Data Mining and Data Analytics, Faculty of Applied Computer Science and Medical Faculty, University of Augsburg, Augsburg, Germany.ORCID 0000-0002-5896-4086
Reiner SiebertInstitute of Human Genetics, Ulm University and Ulm Medical Center, Ulm, Germany.ORCID 0000-0001-7433-3703
Kostiantyn DrevalCanada's Michael Smith Genome Sciences Center, BC Cancer Research Centre, Vancouver, Canada.ORCID 0000-0002-6214-2843
Ryan D MorinCanada's Michael Smith Genome Sciences Center, BC Cancer Research Centre, Vancouver, Canada.ORCID 0000-0003-2932-7800
Loredana MoroDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5111-3465
Michele PaganoDepartment of Biochemistry and Molecular Pharmacology, Laura and Isaac Perlmutter NYU Cancer Center, NYU Grossman School of Medicine, New York, New York.ORCID 0000-0003-3210-2442
Louis M StaudtLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.ORCID 0000-0002-1735-2892
Megan S LimDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-0415-2867
Kojo S J Elenitoba-JohnsonDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-1082-1545
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Regulation of the cell proliferation by CRL ubiquitin ligases-diversity supplementR35GM136250 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MICHELE PAGANO · 2020 to 2026
$2.7M
Role of FBXO45 in Diffuse Large B Cell Lymphoma PathogenesisR01CA231021 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ELENITOBA-JOHNSON, KOJO S. J. · 2019 to 2023
$2.5M
Innate DNA sensing in rapidly progressing IPFR01HL123899 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI HOGABOAM, CORY M · 2015 to 2018
$2.0M
National Institutes of Health (NIH) R01CA231021NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA231021NHLBI NIH HHS R01 HL123899NIGMS NIH HHS R35 GM136250
6 · The paper itself
Abstract
significanceWe describe the identification of a previously unrecognized ubiquitin ligase-substrate (FBXO45-GEF-H1) regulatory axis that plays an important role in germinal center formation and pathogenesis of common BCLs. These studies reveal novel insights linking dysregulated ubiquitin-mediated control to exploitable vulnerabilities and novel therapeutic strategies for these cancers.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The FBXO45-GEF-H1 Axis Controls Germinal Center Formation and B-cell Lymphomagenesis. · full record | OpenQuestion